Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-243 in Relapsed or Refractory AML or MDS
NCT03816319Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of TAK-243 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Primary endpoint: Recommended Phase 2 Dose at 21 days. Started Mar 2025; status: active, not recruiting.
02
Drugs
TAK-243
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03816319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816319.